Executive Interview: Isofol's Anders Rabbe On Its Single-Asset Strategy
Executive Summary
Sweden’s Isofol Medical is showing how a single-asset strategy can attract support from institutional and public market investors, and underpin a multi-year development plan that, it is hoped, will take the company’s cancer therapy through to marketing approval.